Detecting T-cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab.

Background: Trials and real-life studies demonstrated clinically meaningful improvements of disease activity in the majority of patients with moderate to severe atopic dermatitis (AD) treated with the anti-IL-4RA-antibody dupilumab. However, misdiagnosis or confounding skin diseases in particular cutaneous T-cell lymphoma (CTCL) may lead to inadequate response.

Objective: To investigate the clinical and pathological features of patients with AD who showed insufficient response to dupilumab.